InMed Pharmaceuticals (INM) holder buys 1,000 common shares via ADAR1

Rhea-AI Filing Summary

Private investment funds managed by ADAR1 Capital Management, LLC, a ten percent owner of InMed Pharmaceuticals, purchased 1,000 Common Shares on July 15, 2026 at $1.555 per share, increasing their indirect holdings to 801,000 shares. ADAR1 and Daniel Schneeberger may be deemed indirect owners but each disclaims beneficial ownership except for any pecuniary interest. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 1,000 shares ($1,555)

Net Buy 1 txn

Insider ADAR1 Capital Management, LLC, Schneeberger Daniel

Role 10% Owner | 10% Owner

Bought 1,000 shs ($2K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	1,000	$1.555	$2K

Holdings After Transaction: Common Shares — 801,000 shares (Indirect, See Footnote)

Footnotes (1)

1. The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Key Figures

Shares Purchased: 1,000 Common Shares Purchase Price: $1.555 per share Shares Owned After Transaction: 801,000 shares +1 more

4 metrics

Shares Purchased 1,000 Common Shares Non-derivative purchase on July 15, 2026

Purchase Price $1.555 per share Price for the 1,000-share Common Shares transaction

Shares Owned After Transaction 801,000 shares Indirect holdings by funds managed by ADAR1 following the purchase

Net Buy Shares 1,000 shares transactionSummary reports a net-buy of 1,000 shares

Key Terms

indirectly beneficially owned, pecuniary interest, Section 16 of the Securities Exchange Act of 1934, ten percent owner

4 terms

indirectly beneficially owned regulatory

"may be deemed to be indirectly beneficially owned by (i) ADAR1"

pecuniary interest regulatory

"disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest"

Section 16 of the Securities Exchange Act of 1934 regulatory

"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

ten percent owner financial

"is_ten_percent_owner: 1"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 07:29 PM Accepted by SEC EDGAR 07/17/2026 - 07:29 PM Learn about SEC filing dates

FAQ

What insider transaction did InMed Pharmaceuticals (INM) report in this Form 4?

InMed Pharmaceuticals reported that private funds managed by ADAR1 Capital Management purchased 1,000 Common Shares on July 15, 2026. The shares were acquired at $1.555 per share, increasing the funds’ indirect position to 801,000 shares of InMed.

Who are the reporting persons in the InMed (INM) Form 4 filing?

The reporting persons are ADAR1 Capital Management, LLC and Daniel Schneeberger, each listed as a ten percent owner. The securities are owned directly by private investment funds managed by ADAR1 and may be deemed indirectly beneficially owned by ADAR1 and Schneeberger.

How many InMed (INM) shares were owned after the reported transaction?

After the transaction, the private investment funds managed by ADAR1 Capital Management held 801,000 Common Shares of InMed. This figure reflects the post-transaction total holdings associated with the reported purchase of 1,000 shares on July 15, 2026.

What was the purchase price in the latest InMed (INM) insider buy?

The reported purchase price was $1.555 per Common Share. The transaction involved acquiring 1,000 shares, and the price information is reported on a per‑share basis for this open‑market or private purchase transaction dated July 15, 2026.

Is the InMed (INM) insider trade linked to a Rule 10b5-1 plan?

No. The filing indicates the transaction was not affirmed under a Rule 10b5-1 trading plan. This means the reported 1,000‑share purchase at $1.555 per share was not executed pursuant to a pre-arranged 10b5‑1 trading arrangement.

Do ADAR1 and Daniel Schneeberger claim full beneficial ownership of the InMed (INM) shares?

No. ADAR1 Capital Management and Daniel Schneeberger disclaim beneficial ownership of the securities, except to the extent of any pecuniary interest. The shares are held directly by private investment funds that ADAR1 manages.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ADAR1 Capital Management, LLC

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/15/2026		P		1,000	A	$1.555	801,000	I	See Footnote(1)(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

ADAR1 Capital Management, LLC

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Schneeberger Daniel

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE, BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

2. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

	ADAR1 Capital Management, LLC By: Daniel Schneeberger, Manager /s/ Daniel Schneeberger	07/17/2026
	/s/ Daniel Schneeberger	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)